Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

OptimizeRx (OPRX) EBITDA (2016 - 2026)

OptimizeRx's EBITDA history spans 16 years, with the latest figure at $8.6 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 135.8% to $8.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.7 million, a 185.32% increase, with the full-year FY2025 number at $11.8 million, up 186.76% from a year prior.
  • EBITDA hit $8.6 million in Q4 2025 for OptimizeRx, up from $2.0 million in the prior quarter.
  • Over the last five years, EBITDA for OPRX hit a ceiling of $8.6 million in Q4 2025 and a floor of -$10.9 million in Q4 2023.
  • Historically, EBITDA has averaged -$2.0 million across 5 years, with a median of -$2.8 million in 2023.
  • Biggest five-year swings in EBITDA: plummeted 9937.02% in 2022 and later soared 185.06% in 2025.
  • Tracing OPRX's EBITDA over 5 years: stood at $621080.0 in 2021, then plummeted by 239.17% to -$864348.0 in 2022, then crashed by 1161.41% to -$10.9 million in 2023, then skyrocketed by 133.33% to $3.6 million in 2024, then surged by 135.8% to $8.6 million in 2025.
  • Business Quant data shows EBITDA for OPRX at $8.6 million in Q4 2025, $2.0 million in Q3 2025, and $3.2 million in Q2 2025.